Conference Track

Hematologic Malignancies

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Society of Clinical Oncology*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Lenalidomide Effective in Patients With Transfusion-Dependent Myelodysplastic Syndrome and del5q31
Heat Shock Protein 90 Inhibitor Active in Relapsed Refractory Multiple Myeloma
Capecitabine Plus Oxaliplatin Versus 5-Fluorouracil Plus Oxaliplatin Equally Effective and Safe as First-Line Treatment of Metastatic Colorectal Cancer
Bortezomib May Override Poor Prognosis Associated With Chromosome 13 Deletion in Multiple Myeloma
Addition of Thalidomide to Standard Therapy Improves Response and Event-Free Survival in Previously Untreated Patients With Multiple Myeloma
No Significant Differences Between BEACOPP and ABVD Regimens or Different Doses of Radiation Therapy in Intermediate-Stage Hodgkin's Disease
High-Dose Chemotherapy Combined With Autologous Hemopoietic Stem Cell Transplantation Superior to Conventional Chemotherapy for Treatment of Recurrent Hodgkin's Disease
Risk-Adapted Treatment Strategy Results in Improved Outcomes in Acute Promyelocytic Leukemia
Induction Cytarabine and High-Dose Mitoxantrone Increased Response in Acute Lymphoblastic Leukemia Over Standard Treatment
Efficacy and Tolerability of High-Dose Imatinib for Chronic Myeloid Leukemia Confirmed in Phase 2 Multicenter Study
Activity of BMS-354825 in Patients With Imatinib-Resistant Chronic Myeloid Leukemia
BMS-354825 Efficacious and Well Tolerated in Imatinib-Resistant or Intolerant Patients With Chronic Myeloid Leukemia
HIV-DLCL: Significant Improvements in Outcome During Post-HAART Era Suggest New Prognostic Indicators for Survival
Rituximab Plus Chemotherapy Improves Outcome in Advanced Follicular NHL, Regardless of Patient Prognostic Variables
Rituximab Maintenance Therapy Prolongs Remission in Patients With Follicular or Mantle Cell Lymphoma
Addition of Rituximab to FCM Chemotherapy Improves Response and Survival in Recurrent Follicular and Mantle Cell Lymphoma
Rituximab Added to CHOP-Like Regimens Improves Efficacy in Good Prognosis Patients With Diffuse Large B-Cell Lymphoma
DA-EPOCH-R Effective and Safe for Patients With Diffuse Large B-Cell Lymphoma
Bortezomib Safe and Effective in High-Risk Patients With Relapsed Myeloma
Bortezomib-Induced Osteoblast Activation Correlated With Response in Patients With Multiple Myeloma
Decitabine Significantly Improves Clinical Benefit for Patients With Advanced Myelodysplastic Syndrome
Low-Dose Decitabine Well Tolerated and Effective in Intermediate or Advanced Myelodysplastic Syndrome
Bortezomib Active and Well-Tolerated in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Bortezomib-Related Thrombocytopenia Appears Transient and Resolves Spontaneously Between Cycles
Maintenance of Thalidomide/Dexamethasone Feasible and Safe in Multiple Myeloma Patients Not Undergoing Transplant
Bortezomib Plus Dexamethasone Induction Therapy Safe and Effective in Multiple Myeloma
Lenalidomide Plus Dexamethasone Significantly Prolongs Time to Progression and Improves Treatment Response in Patients With Refractory Multiple Myeloma

Expert Analysis

Hematologic Malignancies

Program Director:
Roy A. Beveridge, MD

Faculty:
Kenneth Anderson, MD Hagop M. Kantarjian, MD Alexandra M. Levine, MD
Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe new treatments, and the relationship between cytogenetics and outcome, in patients with multiple myeloma
List current approaches to therapy for patients transfusion-dependent and advanced myelodysplastic syndromes
Recount investigational approaches to achieving hematologic, cytogenetic and molecular responses in untreated or imatinib-resistant chronic myeloid leukemia
Describe strategies for treatment and maintenance in large cell, follicular, mantle cell and HIV-related lymphomas

Earn CME credit by reading the expert analysis and commentary on hematologic malignancies. Topics covered include:

Acute Leukemia/Myelodysplasia
High-dose Imatinib in Chronic Myeloid Leukemia
High-dose Imatinib in Chronic Myeloid Leukemia
BMS354825 for Chronic Myeloid Leukemia
AMN107 in Accelerated and Blastic Phase CML
PETHEMA LPA99
L-20 Regimen in ALL
Multiple Myeloma
Thalidomide in Multiple Myeloma
CKS1B Expression and Survival in Multiple Myeloma
Effect of Bortezomib on Chromosome 13 Deletion
Bortezomib as Induction Therapy in Myeloma
Thalidomide and Dexamethasone in Stem Cell Transplantation
17-AAG in Myeloma
Lymphoma
Rituximab in Large B-Cell Lymphoma
EPOCH in Large B-Cell Lymphoma
Rituximab in Follicular Lymphoma
Rituximab in Relapsed Follicular and Mantle Cell Lymphomas
Bortezomib in Relapsed Mantle Cell Lymphoma
Bendamustine and Rituximab in Relapsed Lymphoma

CME CREDIT INFORMATION

Release Date: 07/21/05

Expiration Date: 07/20/06

Physicians: maximum of 1.75 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.8 contact hours (0.18 CEUs)

Registered Nurses: 2 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.